SCNI (Scinai Immunotherapeutics) YoY EBITDA Growth: 167.87% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNI Scinai Immunotherapeutics Ltd SCNI
20 GF Score
Price $1.95
! 2 Warning Signs
View Full Analysis

What is Scinai Immunotherapeutics YoY EBITDA Growth?

Scinai Immunotherapeutics SCNI -16.67% 20 YoY EBITDA Growth is 167.87% as of Jun. 2026. GuruFocus rates SCNI with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scinai Immunotherapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 167.87%.

Scinai Immunotherapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $4.28.

Scinai Immunotherapeutics YoY EBITDA Growth Related Terms

Scinai Immunotherapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Scinai Immunotherapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinai Immunotherapeutics YoY EBITDA Growth Chart

Scinai Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,826.25 62.88 79.66 273.35 -128.84

Scinai Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.85 38.40 -100.00 72.90 167.87
SCNI
20GF Score
Scinai Immunotherapeutics Ltd SCNI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinai Immunotherapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scinai Immunotherapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-28.013-97.123)/ | 97.123 |
=-128.84 %

Scinai Immunotherapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(4.28--6.306)/ | -6.306 |
=167.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 167.87% mean?
Scinai Immunotherapeutics (SCNI) has a YoY EBITDA Growth of 167.87% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scinai Immunotherapeutics and its competitors.
Is Scinai Immunotherapeutics' YoY EBITDA Growth too high?
Scinai Immunotherapeutics' current YoY EBITDA Growth is 167.87%. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' YoY EBITDA Growth compare to BBLG and PTIX?
Scinai Immunotherapeutics' YoY EBITDA Growth of 167.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scinai Immunotherapeutics and its competitors. Scinai Immunotherapeutics's current YoY EBITDA Growth is 167.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (SCNI) has a current YoY EBITDA Growth of 167.87%. The current YoY EBITDA Growth is 167.87%. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Scinai Immunotherapeutics (SCNI), the current YoY EBITDA Growth is 167.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scinai Immunotherapeutics Business Description

Address Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score

Get the complete analysis for SCNI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.95
Price